Close-up showing business people discussing the facts and figures shown on their charts

Collagen CEO pleased with progress

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical-grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces its final results for the year ended 31 March 2017.

Financial Highlights

  • Group revenue and other income increased by 26% to £4.09 million
  • Net cash balances at 31 March 2017: £8.98 million
  • Balance sheet strengthened with up to £10.8 million (gross) in equity and venture debt facility

Operational Highlights

  • Commercial organisation delivered nine new commercial agreements
  • Online U.S. sales launch to provide additional access to the research markets
  • 60% stake taken in Cre8ive Collagen to move into Chinese market
  • Strengthened executive team with key R&D, Sales and Marketing, and General Management hires
  • Provisional patent for bone graft substitute filed
  • Australian patent for sourcing ultra-thin processed pericardium granted
  • Participation in second major Horizon 2020 project

Jamal Rushdy, Chief Executive Officer of Collagen Solutions, commented: “I am pleased with the progress our team has made over the past year with our new focused strategy to deliver growth in our core supply, development, and manufacturing business through several commercial initiatives, and to build strategic value with our proprietary products R&D pipeline. In addition, our recent financing at the end of the financial year strengthened our balance sheet to fuel these growth initiatives. Finally, we strengthened our leadership team with three key appointments in Sales and Marketing, Research and Development, and General Management. With this momentum, funding, and team in place we remain positive about our vision to be the industry’s first choice in regenerative biomaterials and progress towards our goals to deliver our revenue growth and profitability targets.”


Seen the results in full here

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.